Short Interest in Gyrodyne , LLC (NASDAQ:GYRO) Expands By 407.5%

Posted by Tyrone Williams on Feb 13th, 2026

Gyrodyne , LLC (NASDAQ:GYRO – Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 203 shares, an increase of 407.5% from the January 15th total of 40 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 1,544 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 1,544 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Gyrodyne Stock Up 1.2%

GYRO stock opened at $8.85 on Friday. The business has a 50 day moving average of $9.04 and a 200-day moving average of $9.66. Gyrodyne has a 12-month low of $6.80 and a 12-month high of $12.00.

Hedge Funds Weigh In On Gyrodyne

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRO. Susquehanna International Group LLP bought a new stake in Gyrodyne in the third quarter worth about $142,000. Advisory Services Network LLC purchased a new stake in shares of Gyrodyne during the 3rd quarter worth approximately $77,000. Bulldog Investors LLP bought a new stake in shares of Gyrodyne in the 3rd quarter worth approximately $601,000. Finally, Teton Advisors LLC purchased a new position in Gyrodyne in the third quarter valued at approximately $177,000. 71.36% of the stock is owned by hedge funds and other institutional investors.

About Gyrodyne

(Get Free Report)

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.